Landscape of X chromosome inactivation across human tissues

Autor: Tukiainen, Taru, Villani, Alexandra-Chloé, Yen, Angela, Rivas, Manuel A, Marshall, Jamie L, Satija, Rahul, Aguirre, Matt, Gauthier, Laura, Fleharty, Mark, Kirby, Andrew, Cummings, Beryl B, Castel, Stephane E, Karczewski, Konrad J, Aguet, François, Byrnes, Andrea, GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA, Biospecimen Collection Source Site—NDRI, Biospecimen Collection Source Site—RPCI, Biospecimen Core Resource—VARI, Brain Bank Repository—University of Miami Brain Endowment Bank, Leidos Biomedical—Project Management, ELSI Study, Genome Browser Data Integration &Visualization—EBI, Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz, Lappalainen, Tuuli, Regev, Aviv, Ardlie, Kristin G, Hacohen, Nir, MacArthur, Daniel G

Publikováno v: Nature, vol 550, iss 7675

X chromosome inactivation (XCI) silences transcription from one of the two X chromosomes in female mammalian cells to balance expression dosage between XX females and XY males. XCI is, however, incomplete in humans: up to one-third of X-chromosomal g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::0a24cb9a9dc84dd453f14933ec92f26e
https://escholarship.org/uc/item/3j47t40b

Mitochondrial control of cell bioenergetics in Parkinson's disease

Autor: Requejo-Aguilar, Raquel, Bolanos, Juan P.

Parkinson disease (PD) is a neurodegenerative disorder characterized by a selective loss of dopaminergic neurons in the substantia nigra. The earliest biochemical signs of the disease involve failure in mitochondrial-endoplasmic reticulum cross talk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2636::b2af63a71d38d6807e7ad2aa6532cdd9
https://europepmc.org/articles/pmc5065935?pdf=render

In vivo delta opioid receptor internalization controls behavioral effects of agonists

Autor: Claire Gaveriaux-Ruff, Grégory Scherrer, Brigitte L. Kieffer, Jérôme A.J. Becker, Dominique Filliol, Audrey Matifas, Amynah A. Pradhan, Dominique Massotte, Petra Tryoen-Toth

Publikováno v: PLoS ONE
PLoS ONE, Public Library of Science, 2009, 4 (5), pp.e5425. ⟨10.1371/journal.pone.0005425⟩
PLoS ONE, 2009, 4 (5), pp.e5425. ⟨10.1371/journal.pone.0005425⟩
PLoS ONE, Vol 4, Iss 5, p e5425 (2009)

Background: GPCRs regulate a remarkable diversity of biological functions, and are thus often targeted for drug therapies. Stimulation of a GPCR by an extracellular ligand triggers receptor signaling via G proteins, and this process is highly regulat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b172f7db1dbac5f4c950dfa3278d7674
https://www.hal.inserm.fr/inserm-00387875/document

The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female mice.

Autor: Wingfield KK; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; T32 Biomolecular Pharmacology Training Program, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Misic T; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., Jain K; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., McDermott CS; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., Abney NM; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., Richardson KT; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; Post-Baccalaureate Research Education Program, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Rubman MB; NIH/NIDA Summer Undergraduate Fellowship Program, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Beierle JA; T32 Biomolecular Pharmacology Training Program, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Transformative Training Program in Addiction Science, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Miracle SA; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; Graduate Program for Neuroscience, Boston University, Boston, MA, USA., Sandago EJ; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., Baskin BM; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; T32 Training Program on Development of Medications for Substance Use Disorders Fellowship, Center for Drug Discovery, Northeastern University, Boston, MA, USA., Lynch WB; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; Transformative Training Program in Addiction Science, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Graduate Program for Neuroscience, Boston University, Boston, MA, USA., Borrelli KN; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA.; T32 Biomolecular Pharmacology Training Program, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Transformative Training Program in Addiction Science, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Graduate Program for Neuroscience, Boston University, Boston, MA, USA., Yao EJ; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA., Wachman EM; Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA, USA., Bryant CD; Laboratory of Addiction Genetics, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, 140 The Fenway, Boston, MA, USA. c.bryant@northeastern.edu.

Publikováno v: Psychopharmacology [Psychopharmacology (Berl)] 2024 Sep 30. Date of Electronic Publication: 2024 Sep 30.

Incubation of methamphetamine craving in punishment-resistant individuals is associated with activation of specific gene networks in the rat dorsal striatum.

Autor: Daiwile AP; Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, MD, 21224, USA., McCoy MT; Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, MD, 21224, USA., Ladenheim B; Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, MD, 21224, USA., Subramaniam J; Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, MD, 21224, USA., Cadet JL; Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, MD, 21224, USA. jcadet@intra.nida.nih.gov.

Publikováno v: Molecular psychiatry [Mol Psychiatry] 2024 Jul; Vol. 29 (7), pp. 1990-2000. Date of Electronic Publication: 2024 Feb 14.